A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 mcg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patients with refractory diabetic macular oedema.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary)
Indications Diabetic macular oedema
Focus Registrational; Therapeutic Use
Acronyms OZDRY

Most Recent Events

01 Dec 2015 Status changed from active, no longer recruiting to completed, as per an article published in the Eye.
18 Jan 2014 Status changed from recruiting to active, no longer recruiting (Closed - in follow-up) as reported by United Kingdom Clinical Research Network record.
11 Dec 2013 Accrual to date is 102% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight